Routine Electronic Patient-reported Outcome Measures During and After Radiotherapy: A Randomized Controlled Study
Condition(s) studied
Investigational drug(s) / intervention(s)
PRO-CTCAE, Pain NRS: The Common Terminology Criteria for Adverse Events (PRO-CTCAE) is a PROM developed to systematically and objectively reflect patients' experiences and perceptions of therapeutic drugs in toxicity evaluation and adverse event reporting. PRO-CTCAE can be used to monitor patients' symptoms and side effects, support therapeutic decision-making, facilitate communication among medical staff, implement patient-centred care, and screen for health conditions.
Study summary
Patients in this study will be asked to periodically self-report their symptoms using their smartphones during the radiotherapy period and during the acute phase (3 months) after treatment, and radiation oncology physicians will evaluate the impact on cancer patients' quality of life and determine whether they can improve health outcomes by using this data in their practice.
Eligibility
Primary outcome measure(s)
- Mean change score from baseline in Quality of Life Assessment Tool (EORTC-QLQ-C30) — 36 months after registration
Comparison of quality of life assessment tool scores between groups is performed using independent t-test. Linear mixed-effect model is used in the intention-to-treat study population. Age, sex, pretreatment PROM score, cancer type, and stage are controlled as fixed covariates, and radiation oncology and attending physician are controlled as random intercepts. For sensitivity analysis, additional analysis is performed on patients who completed more than 80% of the REPROM questionnaire. Since this study is an exploratory analysis, a two-sided significance level of .05 is used for all comparisons without redundancy adjustment.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Yongin Severance Hospital | Yongin-si | South Korea | Recruiting |
More Yonsei University trials in South Korea
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06598293 on ClinicalTrials.gov ↗ ← All trials in South Korea